摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sodium adeninate

中文名称
——
中文别名
——
英文名称
sodium adeninate
英文别名
adenine sodium salt;sodium adenide;sodium;9H-purin-3-id-6-imine
sodium adeninate化学式
CAS
——
化学式
C5H4N5*Na
mdl
——
分子量
157.11
InChiKey
GDQWMVUOVOVACL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.43
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    65.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    15-冠醚-5sodium adeninate二甲基亚砜 为溶剂, 生成
    参考文献:
    名称:
    通过核磁共振、紫外光谱和晶体学对二甲基亚砜中腺苷酸盐的阳离子-阴离子相互作用和自聚集的分子理解
    摘要:
    核酸的稀有阴离子形式发挥着重要的生物学作用,并导致自发突变、复制和翻译错误。缺乏关于这些形式的稳定性和反应性的信息。DMSO 溶液中存在腺嘌呤的单钠盐和钾盐离子对,在嘌呤环的 N1、N7 和 N9 原子上可能有阳离子配位点。随着浓度的增加,π-π 堆积二聚体是聚集体的主要种类,其次是由与金属阳离子配位控制的高阶聚集体,其中存在的抗衡离子类型在聚集体形成中起核心作用。
    DOI:
    10.1002/cphc.202100098
  • 作为产物:
    描述:
    腺嘌呤 在 sodium hydride 作用下, 以 二甲基亚砜 为溶剂, 生成 sodium adeninate
    参考文献:
    名称:
    通过核磁共振、紫外光谱和晶体学对二甲基亚砜中腺苷酸盐的阳离子-阴离子相互作用和自聚集的分子理解
    摘要:
    核酸的稀有阴离子形式发挥着重要的生物学作用,并导致自发突变、复制和翻译错误。缺乏关于这些形式的稳定性和反应性的信息。DMSO 溶液中存在腺嘌呤的单钠盐和钾盐离子对,在嘌呤环的 N1、N7 和 N9 原子上可能有阳离子配位点。随着浓度的增加,π-π 堆积二聚体是聚集体的主要种类,其次是由与金属阳离子配位控制的高阶聚集体,其中存在的抗衡离子类型在聚集体形成中起核心作用。
    DOI:
    10.1002/cphc.202100098
  • 作为试剂:
    描述:
    2-(2-(苄氧基)乙基)环氧乙烷腺嘌呤sodium adeninate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 22.0h, 以61%的产率得到9-<4-(benzyloxy)-2-hydroxybutyl>adenine
    参考文献:
    名称:
    Synthesis of 9-(4-hydroxy-2-oxobutyl)guanine, 9-(2,4-dihydroxybutyl)guanine and related acyclic nucleoside analogs
    摘要:
    DOI:
    10.1021/jo00206a005
点击查看最新优质反应信息

文献信息

  • Preparation of enantiomeric and racemic 2,3,4,5-tetrahydroxypentyl derivatives of adenine, cytosine and uracil
    作者:Antonín Holý
    DOI:10.1135/cccc19822786
    日期:——

    1-(Adenin-9-yl)-1-deoxy-DL-ribitol (III), -D-arabitol (IXa), -L-arabitol (XIVa), -DL-xylitol (XXIVa), 1-(cytosin-L-yl)-1-deoxy-D-arabitol (IXb), -L-arabitol (XIVb), 1-(uracil-1-yl)-1-deoxy-D-arabitol (IXc), -L-arabitol (XIVc) and -DL-xylitol (XXIVb) were prepared by reaction of 1-O-p-toluenesulfonyl-2,3:4,5-di-O-isopropylidenealditols Ib, VIIb, XIIb and XXIIb with sodium salts of adenine, N4-benzoylcytosine or 4-methoxy-2-pyrimidone followed by removal of the protecting groups. Condensation of the mentioned sodium salts with methyl 5-O-p-toluenesulfonyl-2,3-O-isopropylidene-β-D-ribofuranoside (IV) with subsequent acid hydrolysis and reduction with sodium borohydride afforded 1-(adenin-9-yl)-1-deoxy-L-ribitol (VIa) and 1-(cytosin-1-yl)-1-deoxy-L-ribitol (VIb). 1-(Adenin-9-yl)-1-deoxy-L-lyxitol (XVII), -L-lyxitol (XVIII) and -2-O-methyl-D-lyxitol (XXI) were prepared analogously. Acid hydrolysis of 5-(adenin-9-yl)-5-deoxy-4-O-benzyl-1,2-O-isopropylidene-α-D-xylofuranose (XXVa), followed by reduction with sodium borohydride and catalytic hydrogenation, gave 1-(adenin-9-yl)-1-deoxy-L-xylitol (XXVIb).

    1-(腺嘌呤-9-基)-1-脱氧-DL-核糖醇(III),-D-阿拉伯糖醇(IXa),-L-阿拉伯糖醇(XIVa),-DL-木糖醇(XXIVa),1-(胞嘧啶-L-基)-1-脱氧-D-阿拉伯糖醇(IXb),-L-阿拉伯糖醇(XIVb),1-(尿嘧啶-1-基)-1-脱氧-D-阿拉伯糖醇(IXc),-L-阿拉伯糖醇(XIVc)和-DL-木糖醇(XXIVb)通过将1-O-p-甲苯磺酰基-2,3:4,5-二-O-异丙基亚甲基二醇(Ib,VIIb,XIIb)和(XXIIb)与腺嘌呤、N4-苯甲酰胞嘧啶或4-甲氧基-2-嘧啶酮的钠盐反应制备,随后去除保护基。提到的钠盐与甲基5-O-p-甲苯磺酰基-2,3-O-异丙基亚-D-核糖呋喃苷(IV)缩合,随后进行酸水解和硼氢化钠还原,得到1-(腺嘌呤-9-基)-1-脱氧-L-核糖醇(VIa)和1-(胞嘧啶-1-基)-1-脱氧-L-核糖醇(VIb)。1-(腺嘌呤-9-基)-1-脱氧-L-利克糖醇(XVII),-L-利克糖醇(XVIII)和-2-O-甲基-D-利克糖醇(XXI)类似制备。5-(腺嘌呤-9-基)-5-脱氧-4-O-苄基-1,2-O-异丙基亚-D-木糖呋喃糖醇(XXVa)的酸水解,随后与硼氢化钠还原和催化氢化,得到1-(腺嘌呤-9-基)-1-脱氧-L-木糖醇(XXVIb)。
  • 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
    申请人:Wayne State University
    公开号:US06352991B1
    公开(公告)日:2002-03-05
    Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopurine, 2-amino-6-azidopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine (hypoxanthine), 2-amino-6-halo substituted purines, 2-amino-6-alkoxy substituted purines, 2-amino-6-hydroxypurine (guanine), 3-deazapurines, 7-deaza-purines, 8-azapurines, cytosine, 5-halo substituted cytosines, 5-alkyl substituted cytosines, thymine, uracil and 6-azapyrimidines; X is O; and, R1 and R2 are alkyl or aryl groups. The compounds of the present invention also include the R- and S-enantiomers of the above compounds. The R1X and/or R2X can also be amino acid residues with X as NH.
    具有抗病毒活性的化合物具有以下配方:其中B是嘌呤或嘧啶杂环环,最好从包括6-氨基嘌呤(腺嘌呤)、2,6-二氨基嘌呤、2-氨基-6-偶氮基嘌呤、2-氨基-6-环丙胺基嘌呤、6-羟基嘌呤(次黄嘌呤)、2-氨基-6-卤代嘌呤、2-氨基-6-烷氧基嘌呤、2-氨基-6-羟基嘌呤(鸟嘌呤)、3-去氮嘌呤、7-去氮嘌呤、8-氮杂嘌呤、胞嘧啶、5-卤代胞嘧啶、5-烷基取代胞嘧啶、胸腺嘧啶、尿嘧啶和6-氮杂嘧啶中选择;X为O;R1和R2是烷基或芳基基团。本发明的化合物还包括上述化合物的R-和S-对映体。R1X和/或R2X也可以是带有X为NH的氨基酸残基。
  • Open-Chain Carbocyclic Analogs of Adenosine with Dihalovinyl Unit as Potential Inhibitors of<i>S</i>-Adenosyl-<scp>L</scp>-homocysteine Hydrolase
    作者:Elzbieta Lewandowska、Jennifer Lalama、Chong-Sheng Yuan、Stanislaw F. Wnuk
    DOI:10.1081/ncn-120023270
    日期:2003.10
    6'-halo(homovinyl)adenosines, which are known to be potent inhibitors of S-adenosyl-L-homocysteine hydrolase. Swern oxidation of 9-[3-(t-butyldimethylsilyloxy)-4-hydroxybutyl]adenine (4) followed by Wittig olefination and desilylation gave access to ethyl 6-(adenin-9-yl)-4-hydroxy-2(E)-hexenoate (7) and 5-(adenin-9-yl)-1,1-dibromo-1-penten-3-ol (9). No inhibition of AdoHcy Hydrolase was observed with
    合成了乙烯基延伸的脱氧金属腺嘌呤衍生物,作为6'-卤代(homovinyl)腺苷的无环/碳环类似物,已知它们是S-腺苷-L-高半胱氨酸水解酶的有效抑制剂。对9- [3-(叔丁基二甲基甲硅烷氧基)-4-羟基丁基]腺嘌呤(4)进行剧烈氧化,然后进行Wittig烯化和甲硅烷基化反应,得到乙基6-(腺嘌呤-9-基)-4-羟基-2(E) -己酸(7)和5-(腺嘌呤-9-基)-1,1-二溴-1-戊烯-3-醇(9)。用7和9未观察到对AdoHcy水解酶的抑制。
  • [5-(Adenin-9-yl)-5-deoxy-L-pentofuranosyl]phosphonates - A Novel Type of Nucleotide Analogs Related to HPMPA. II. Synthesis of L-ribo and L-xylo Configurated Derivatives by Recyclization of Diethyl (5-RS)-[1,2-O-Isopropylidene-5-O-methanesulfonyl-D-pentofuranos-5-C-yl]phosphonates under Acidic Conditions
    作者:Miroslav Otmar、Ivan Rosenberg、Milena Masojídková、Antonín Holý
    DOI:10.1135/cccc19932180
    日期:——

    Further cyclic analogs of the antiviral (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine (I) were prepared: both anomers of [5-(adenin-9-yl)-5-doxy-L-ribofuranosyl]phosphonic acid (α-IId and β-IId) and [5-(adenin-9-yl)-5-doxy-α-L-ribofuranosyl]phosphonic acid (IIe). Recyclization reaction of diethyl (5RS-(3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-D-ribofuranos-5-C-yl)phosphonate (IVb) and diethyl (5RS-(3-O-benzyl-1,2-O-isopropylidene-5-O-methanesulfonyl-D-xylofuranos-5-C-yl)phosphonate (IVd) in trifluoroacetic acid led to cyclic aldehydes Va and Vb which were reduced to diethyl α- and β-L-ribofuranosylphosphonates VIb and α-L-xylofuranosylphosphonate VIIb. Conversion to the protected 5-O-tosylates VId and VIId, followed by reaction with adenine and deprotection, afforded the mentioned nucleotide analogs IId and IIe. An attempt to prepare L-pentofuranosylphosphonates Vc and XIII, suitable for the synthesis of nucleotide analogs of 3-deoxy-L-erythro and L-xylo configuration (IIf and IIg, respectively) by the recyclization reaction of the corresponding 5-O-methanesulfonyl derivatives IVf and XIIb failed. In this case, anhydro derivatives IXa, XVa and XVIa were isolated and identified.

    进一步合成了抗病毒(S)-9-(3-羟基-2-磷酸甲氧基丙基)腺嘌呤(I)的环状类似物:[5-(腺嘌呤-9-基)-5-氧基-L-核糖呋喃磷酸]的两种异构体(α-IId和β-IId)和[5-(腺嘌呤-9-基)-5-氧基-α-L-核糖呋喃磷酸](IIe)。将二乙酸(5RS-(3-O-苄基-1,2-O-异丙基亚甲磺酰基-5-O-甲磺酰基-D-核糖呋喃-5-C-基)磷酸酯(IVb)和二乙酸(5RS-(3-O-苄基-1,2-O-异丙基亚甲磺酰基-5-O-甲磺酰基-D-木糖呋喃-5-C-基)磷酸酯(IVd)在三氟乙酸中进行再循环反应,得到环状醛VaVb,进而还原为二乙酸α-和β-L-核糖呋喃磷酸VIb和α-L-木糖呋喃磷酸VIIb。转化为保护的5-O-对甲苯磺酸酯VIdVIId,随后与腺嘌呤反应并去保护,得到所述的核苷酸类似物IIdIIe。试图合成适用于3-脱氧-L-erythro和L-xylo构型核苷酸类似物(IIfIIg)的L-戊呋喃磷酸酯VcXIII,通过对应的5-O-甲磺酰衍生物IVfXIIb进行再循环反应失败。在这种情况下,被分离和鉴定了无水衍生物IXa, XVaXVIa
  • Total Chemoenzymatic Synthesis of (-)-3′-Methylaristeromycin
    作者:Gérard Audran、Paul Brémond、Yoann Aubin、Honoré Monti
    DOI:10.1055/s-2007-973889
    日期:2007.4
    Enantiopure ethyl (1 S,4 R)-4-hydroxy-2-methylcyclopent-2-ene-1-carboxylate, readily obtained by enzymatic kinetic resolution of the corresponding racemic derivative, provided a convenient starting building block for an 11-step chiral preparation of (-)-3′-methylaristeromycin with 23% overall yield.
    Enantiopure 乙基 (1 S,4 R)-4-hydroxy-2-methylcyclopent-2-ene-1-carboxylate,很容易通过相应外消旋衍生物的酶动力学拆分获得,为 11 步手性提供了方便的起始构建以 23% 的总收率制备 (-)-3'-methylaristeromycin。
查看更多